NB: Concepts represent early planning stages for PAs, RFAs, or RFPs for Council 's input. Council approval does not guarantee that a concept will become an initiative.
If NIAID publishes an initiative from one of these concepts, we link to it below. For a full list of initiatives, go to NIH Funding Opportunities Relevant to NIAID.
Table of Contents
Sexually Transmitted Infections (STI) Cooperative Research Centers
For the published initiative, see the July 16, 2008, Guide announcement.
Request for Applications
Contact: Elizabeth Rogers
Phone: 301-402-0443
Internet: ERogers@niaid.nih.gov
Objective: To stimulate multidisciplinary, collaborative research on Sexually Transmitted Infections (STIs) by advancing the understanding of the pathogenesis of these bacterial and viral agents, and to develop and evaluate control and prevention strategies to reduce the public health impact of these infections.
Description: The goal of this RFA is to fund highly qualified research projects that incorporate and foster collaborative research among investigators from several scientific disciplines, including biomedical, clinical, behavioral, and product development research. Given the range of control and prevention strategies that might be proposed, the areas within these disciplines could include, but are not limited to, microbiology, immunology, molecular biology, adolescent medicine, gynecology, and behavioral science. Examples of potential areas of research and product interest would be interventional and behavioral studies, evaluation of diagnostics, therapeutic agents, vaccines, and microbicides.
Partnership for Point of Care (POC) Diagnostic Technologies for Nontraditional Health Care Settings
For the published initiative, see the March 7, 2008, Guide announcement.
Request for Applications
Contact: Hagit David
Phone: 301-402-4596
Internet: HDavid@niaid.nih.gov
Objective: The goal of this RFA is to advance the development of POC diagnostic technologies for infectious disease causing pathogens and toxins to be utilized in nontraditional health care settings.
Description: The goal of this partnership program is to stimulate industry participation in the development of products using new technologies and methods to improve the POC diagnostic technologies for infectious disease-causing pathogens or toxins in nontraditional health care settings. These methods and technologies may have broad applicability to a variety of body sites and/or specimens, for example the nasopharynx, genital tract, urinary tract, and whole blood. These technologies should be operational in nontraditional settings including home, rural, and urban community public health care clinics, and temporary health care clinics established in response to a natural or man-made disaster. The focus of the research could encompass improved self-collection methodology, home based test kits, and/or public health based POC diagnostic testing. Examples include single unit swab and fluid processing, non-sterile collection devices with preservation capability, and integrated collection and processing methods.
Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance
For the published initiative, see the May 12, 2008, solicitation.
Broad Agency Announcement
Contact: Frank Vidergar
Phone: 301-402-1490
Internet: vidergarf@niaid.nih.gov
Objective: To conduct targeted clinical trials to address the growing public health problem of antimicrobial resistance.
Description: This solicitation targets infectious diseases where improved treatment strategies could reduce the risk of antimicrobial resistance and preserve the effectiveness of existing antimicrobials. Eligible strategies include, but are not limited to: shorter courses of antimicrobial treatment in various diseases; withholding antimicrobials where not indicated; different dosages/frequencies to achieve desirable in vivo efficacy; prudent antimicrobial use; optimal use of off-patent antimicrobials for newly emerging resistance; new indications for licensed products, etc.
Consortium for TB Diagnostic Tools and Strategies
For the published initiative, see the July 23, 2008, solicitation, Tuberculosis Clinical Diagnostics Research Consortium (CDRC).
Request for Proposals
Contact: Andrew Cherry
Phone: 301-402-2443
Internet: cherryan@niaid.nih.gov
Objective: To establish a consortium of clinical research sites to evaluate novel diagnostic tests and strategies for TB in the context of existing clinical diagnostic algorithms.
Description: This solicitation is to establish a consortium of sites for the purpose of evaluating diagnostic tests and strategies in the context of existing clinical algorithms for diagnosis or exclusion of TB. The diagnostic consortium will be comprised of clinical study sites in TB endemic countries with prevalent drug sensitive and drug resistant TB, access to HIV co-infected persons and pediatric populations and with well defined methods for diagnosis of TB. This integrated approach is necessary to assure a new diagnostic test significantly contributes to improving diagnosis of TB and advancing clinical care for the disease. These study sites will already have the capability to execute clinical studies and new infrastructure will not be developed as part of this contract. The consortium will also provide opportunities for outside investigators to develop collaborations with contract staff that may result in grant applications to answer applied and basic questions in TB diagnostic development.
Development of Novel Interventions and Tools for the Control of Malaria, Neglected Tropical Diseases, and Their Vectors
For the published initiative, see the March 7, 2008, Guide announcement.
Request for Applications
Contact: M. John Rogers
Phone: 301-402-8304
Internet: Jrogers@niaid.nih.gov
Objective: The objective of this new initiative is to support translational research leading to the discovery and development of new therapeutics or vector management strategies that will reduce or eliminate morbidity and mortality resulting from malaria and neglected tropical diseases.
Description: This initiative will bridge basic research and product development by supporting cooperative research projects. Specifically, the research proposed would encourage: 1) preclinical development of new therapeutic agents that inhibit parasite targets for the treatment or prevention of disease, or 2) innovative approaches to limit transmission of the parasite at the invertebrate vector level.
|
